Credit Suisse Ag Tyme Technologies, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

Shares

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 14, 2021	SELL	$1.34 - $3.53 $25,594 - $67,423	-19,100 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$0.87 - $1.26 $16,617 - $24,066	19,100 New	19,100 $24,000
Q4 2019 Feb 12, 2020	SELL	$1.0 - $1.49 $12,282 - $18,300	-12,282 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$0.97 - $1.77 $9,749 - $17,790	-10,051 Reduced 45.01%	12,282 $15,000
Q2 2019 Aug 14, 2019	SELL	$0.96 - $1.89 $1,804 - $3,553	-1,880 Reduced 7.76%	22,333 $27,000
Q1 2019 May 14, 2019	BUY	$1.76 - $3.73 $4,857 - $10,294	2,760 Added 12.87%	24,213 $43,000
Q4 2018 Feb 13, 2019	BUY	$2.01 - $4.21 $43,120 - $90,317	21,453 New	21,453 $79,000
Q3 2018 Nov 13, 2018	SELL	$2.18 - $3.44 $24,304 - $38,352	-11,149 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.05 - $4.09 $22,855 - $45,599	11,149 New	11,149 $35,000
Q1 2018 May 15, 2018	SELL	$2.12 - $7.0 $50,498 - $166,740	-23,820 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$3.25 - $7.3 $77,415 - $173,886	23,820	23,820 $152,000

About TYME TECHNOLOGIES, INC.

Ticker TYME
Exchange NASDAQ
Shares Outstandng 172,207,008
Description
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also devel...

More about TYME

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.